Skip links
Clinical Trials

M&A Activity in 2024: Biopharma’s Year of Strategic Consolidation

The biopharma industry is poised for a year of strategic mergers and acquisitions, building on the momentum seen in late 2023. This trend is driven by companies seeking to strengthen their pipelines, expand therapeutic areas, and gain competitive advantages in a rapidly evolving market.

A Strong Foundation from 2023

The stage for 2024’s M&A activity was set by a robust fourth quarter in 2023. Despite fewer overall deals, the quarter saw $37.6 billion in upfront M&A value across 27 transactions. This contributed to a impressive total of $128.8 billion across 112 acquisitions for the full year 2023. Notable deals included AbbVie’s acquisitions of ImmunoGen and Cerevel Therapeutics, signaling a appetite for strategic additions to product portfolios.

Focus on Late-Stage Assets

In 2024, we anticipate a continued shift towards acquiring companies with late-stage assets. This trend is evident in the changing deal landscape of 2023, where Phase I deals nearly doubled to 15, up from 8 in the previous year. The preference for more developed assets is a strategy to mitigate risk and accelerate time-to-market in an increasingly competitive environment.

Key Therapeutic Areas

Oncology and rare diseases are expected to remain prime targets for M&A activity. The oncology sector, which saw $86.1 billion in partnership deal values in 2023, is likely to continue attracting significant interest. Companies with promising cancer therapies, particularly in emerging areas like cell therapies and precision oncology, may find themselves attractive acquisition targets.

Technology-Driven Acquisitions

2024 may see an uptick in acquisitions focused on innovative technologies. The success of antibody-drug conjugates (ADCs), exemplified by the $22 billion Daiichi Sankyo and Merck deal in 2023, could drive similar technology-focused acquisitions. Companies with proprietary platforms in areas like gene editing, RNA therapeutics, or novel drug delivery systems may become prime targets.

Global Perspective

Cross-border M&A activity is expected to increase as companies seek to expand their global footprint. Chinese companies, in particular, may look to acquisitions as a means to enter Western markets, while Western pharma giants might eye Asian biotechs to gain a foothold in rapidly growing markets like China and India.

Challenges and Considerations

While the outlook for M&A is generally positive, several factors could influence deal-making in 2024:

  1. Regulatory Scrutiny: Increased regulatory oversight, particularly for larger deals, may impact timelines and deal structures.
  2. Valuation Gaps: Differing expectations between buyers and sellers could slow down some negotiations.
  3. Geopolitical Factors: Global tensions and trade policies may affect cross-border transactions.
  4. Financing Environment: The availability and cost of capital will play a crucial role in deal-making.

Potential Mega-Deals

Industry analysts are watching for potential mega-deals that could reshape the biopharma landscape. While specific predictions are speculative, areas ripe for large-scale consolidation include immuno-oncology, gene therapy, and companies with strong rare disease portfolios.


2024 is shaping up to be a year of strategic consolidation in the biopharma industry. Companies will likely pursue M&A not just for immediate pipeline gains, but as part of broader strategies to position themselves in an increasingly complex and competitive global market. Successfully navigating this landscape will require a delicate balance of strategic vision, financial acumen, and regulatory savvy.

As the year unfolds, we can expect to see a mix of bolt-on acquisitions to fill pipeline gaps, strategic purchases to enter new therapeutic areas or geographical markets, and potentially transformative mega-mergers that could redraw the industry map. For biopharma executives, investors, and industry observers, 2024 promises to be a year of significant activity and strategic maneuvering in the M&A space.

Leave a comment